Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
SummaryQuotesChartsNewsRatingsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alexion Pharmaceuticals : SVB Leerink Downgrades Alexion Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $156 From $196

03/23/2021 | 06:40am EST


ę MT Newswires 2021
All news about ALEXION PHARMACEUTICALS, INC.
01/25The 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada
AQ
01/10AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurim..
CI
2021M&A market remains strong despite decline in activity
AQ
2021LIFE SCIENCES : Vavilov And The New Regulatory Environment
AQ
2021ALEXION PHARMACEUTICALS : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Exces..
AQ
2021Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in ..
CI
2021OCULAR THERAPEUTIX : Announces appointment of karen-leigh edwards as senior vice president..
AQ
2021AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development ..
CI
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2020 6 070 M - -
Net income 2020 603 M - -
Net cash 2020 68,0 M - -
P/E ratio 2020 57,4x
Yield 2020 -
Capitalization 40 336 M 40 336 M -
EV / Sales 2019 4,81x
EV / Sales 2020 5,62x
Nbr of Employees 3 837
Free-Float 91,0%
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Income Statement Evolution
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ALEXION PHARMACEUTICALS, INC.0.00%40 336
CSL LIMITED-14.20%84 148
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 757
SAMSUNG BIOLOGICS CO.,LTD.-21.15%39 159
BIOGEN INC.-8.74%32 161
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-13.07%27 227